The stock of Ensysce Biosciences Inc (NASDAQ: ENSC) has increased by 6.09 when compared to last closing price of 2.30. Despite this, the company has experienced a 7.96% gain in its stock price over the last five trading sessions. accessnewswire.com reported 2025-06-04 that ~ PF614-MPAR Moving to Next Stage of Development, Finalizing Drug Formulation ~ ~ Funds Accelerate Path Towards Commercialization ~ SAN DIEGO, CA / ACCESS Newswire / June 4, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (“Ensysce” or the “Company”), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced it was awarded the second $5.3 million installment of a $15 million, three-year grant from the National Institute on Drug Abuse (NIDA)1. This continued support will accelerate the clinical and non-clinical development of PF614-MPAR, a next-generation opioid designed to offer powerful pain relief while dramatically reducing the risk of overdose.
Is It Worth Investing in Ensysce Biosciences Inc (NASDAQ: ENSC) Right Now?
ENSC has 36-month beta value of 0.98. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ENSC is 2.33M, and currently, short sellers hold a 14.78% ratio of that float. The average trading volume of ENSC on June 04, 2025 was 1.65M shares.
ENSC’s Market Performance
The stock of Ensysce Biosciences Inc (ENSC) has seen a 7.96% increase in the past week, with a -1.21% drop in the past month, and a -52.21% fall in the past quarter. The volatility ratio for the week is 2.80%, and the volatility levels for the past 30 days are at 6.48% for ENSC. The simple moving average for the past 20 days is 8.60% for ENSC’s stock, with a -54.23% simple moving average for the past 200 days.
ENSC Trading at 1.04% from the 50-Day Moving Average
After a stumble in the market that brought ENSC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.37% of loss for the given period.
#####
#####
Stock Fundamentals for ENSC
Current profitability levels for the company are sitting at:
- -2.44 for the present operating margin
- 0.36 for the gross margin
The net margin for Ensysce Biosciences Inc stands at -2.43. The total capital return value is set at -2.4. Equity return is now at value -200.53, with -140.74 for asset returns.
Based on Ensysce Biosciences Inc (ENSC), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -22.54. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -148.26.
Currently, EBITDA for the company is -6.73 million with net debt to EBITDA at 0.41. When we switch over and look at the enterprise to sales, we see a ratio of 1.09. The receivables turnover for the company is 127.5for trailing twelve months and the total asset turnover is 0.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.50.
Conclusion
To put it simply, Ensysce Biosciences Inc (ENSC) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
